Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 Exhibit 99.1 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2026 SECOND QUARTER AND SIX-MONTH RESULTS IRVINE, CA, January 29, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2026 second quarter ended December 31, 2025. The Company also filed its Quarterly Report on Form 10-Q for the second quarter of fiscal year 2026 with the Securities and Exchange Commission today. Operating expenses (which in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 0-14942 PRO-DEX, INC. (Exact name of registrant as specified in its charter) ——————— COLORADO 84-1261240 (Sta ...

IRVINE, CA / ACCESS Newswire / January 29, 2026 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2026 second quarter ended December 31, 2025. ...

Group 1 - The article does not provide any specific insights or analysis related to companies or industries, focusing instead on the author's credentials and disclosures [1][2][3]

Group 1 - The article does not provide any specific insights or analysis related to companies or industries, focusing instead on the author's credentials and disclosures [1][2][3]

Pro-Dex, Inc. ( PDEX ) manufactures surgical drivers and shavers, used mostly in orthopedic medical devices. I covered the name a few years ago, since when its situation has not changed meaningfully, in a consistent trendLong-only investment, evaluating companies from an operational, buy-and-hold perspective.Quipus Capital does not focus on market-driven dynamics and future price action. Instead, our articles focus on operational aspects, understanding the long-term earnings power of companies, the competit ...

Pro-Dex, Inc. ( PDEX ) manufactures surgical drivers and shavers, used mostly in orthopedic medical devices. I covered the name a few years ago, since when its situation has not changed meaningfully, in a consistent trendLong-only investment, evaluating companies from an operational, buy-and-hold perspective.Quipus Capital does not focus on market-driven dynamics and future price action. Instead, our articles focus on operational aspects, understanding the long-term earnings power of companies, the competit ...

Core Viewpoint - PRO-DEX, INC. has executed a contract amendment with its largest customer, extending the agreement for an additional three years [1] Company Summary - The contract amendment was executed on December 17, 2025, indicating a strong relationship with the largest customer [1]

Core Insights - Long Cast Advisers reported a cumulative net return improvement of 4% in Q3 2025, with a total cumulative return of 266% net of fees since inception in November 2015, translating to a 14% CAGR [1] Company Summary - Pro-Dex, Inc. (NASDAQ:PDEX) is highlighted as a key stock in Long Cast Advisers' Q3 2025 investor letter, specializing in powered surgical instruments for medical device OEMs [2] - The stock of Pro-Dex, Inc. experienced a one-month return of 1.50% but has seen a significant decline of 25.65% over the past 52 weeks, closing at $36.44 per share with a market capitalization of $119.523 million as of November 28, 2025 [2] - Pro-Dex, Inc. issued a press release in mid-September addressing a significant stock decline, clarifying that it is not associated with a blockchain platform sharing the same ticker, and added a risk disclosure regarding potential AI-related errors affecting the stock [3]

Core Insights - Pro-Dex, Inc. (PDEX) reported quarterly earnings of $0.62 per share, exceeding the Zacks Consensus Estimate of $0.50 per share, but down from $0.75 per share a year ago, indicating an earnings surprise of +24.00% [1] - The company generated revenues of $18.53 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 21.11% and up from $14.89 million year-over-year [2] - Pro-Dex shares have declined approximately 34.3% year-to-date, contrasting with the S&P 500's gain of 17.2% [3] Earnings Outlook - The future performance of Pro-Dex's stock will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.59 on revenues of $17.3 million, and for the current fiscal year, it is $2.38 on revenues of $70 million [7] Industry Context - The Medical - Dental Supplies industry, to which Pro-Dex belongs, is currently ranked in the top 21% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]